Frontlight ResearchEarly access
Childhood cancers trials in United States
933 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleGenetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Where
- Columbus
- Age
- 2 years and over
- People
- 54
- Run by
- Sumithira Vasu
See details and how to joinNCT05418088 - Phase 2Taking peopleStudy of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Where
- Ann Arbor, Aurora, Boston, Chicago, Cincinnati, Columbus, Durham, Houston, Philadelphia, Seattle, Washington D.C.
- Age
- 12 months to 39 years
- People
- 120 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT05843253 - Phase 2Taking peopleSelumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
- Where
- Baltimore, Bethesda, Birmingham, Boston, Chicago, Cincinnati, Dallas, Indianapolis, Los Angeles, Palo Alto, Philadelphia, Rochester, St Louis, Washington D.C.
- Age
- 1 year to 8 years
- People
- 200
- Run by
- University of Alabama at Birmingham
See details and how to joinNCT06188741 - Early phase 1Taking peopleA Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
- Where
- Minneapolis
- Age
- 12 years and over
- People
- 8
- Run by
- University of Minnesota
See details and how to joinNCT06693284 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Ann Arbor, Appleton, Athens, Aurora, Baltimore, Bolivar, Boston, Canton, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Detroit, Duarte, Fairfax, Glendale, Goldsboro, Hollywood, Houston, Kingwood, La Jolla, Long Beach, Memphis, New Brunswick, New Orleans, New York, Orange, Peoria, Philadelphia, Saint Paul, Santa Rosa, Seattle, St Louis, Tacoma, Tampa, Toledo, Washington D.C.
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 2Taking peopleDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
- Where
- New York, Stanford
- Age
- 15 years and over
- People
- 30
- Run by
- Jennifer Amengual
See details and how to joinNCT06954805 - Phase 1/2Taking peopleAutologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- Where
- Philadelphia
- Age
- 0 years to 29 years
- People
- 115
- Run by
- Stephan Grupp MD PhD
See details and how to joinNCT05480449 - No phaseNot yet taking people in United StatesICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening
- Where
- Minneapolis
- People
- 7
- Run by
- VA Office of Research and Development
See details and how to joinNCT06745258 - No phaseTaking peopleInternational Pediatric Adrenocortical Tumor Registry
- Where
- Dayton, Fort Worth, Memphis, Stanford, St. Petersburg
- Age
- Up to 21 years
- People
- 9,999
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT00700414 - Phase 1Taking peoplePalbociclib and Pembrolizumab in Sarcoma
- Where
- Iowa City
- Age
- 12 years and over
- People
- 8
- Run by
- John Rieth
See details and how to joinNCT06113809 - No phaseNot yet taking people in United StatesRadiation Treatment Plan Evaluation Learning Tool Pilot Project
- Where
- Boston
- People
- 20
- Run by
- Massachusetts General Hospital
See details and how to joinNCT06115811 - Phase 2Taking peopleRetinoblastoma Phase II Expanded Access Clinical Trial
- Where
- Milwaukee, New York
- Age
- Up to 8 years
- People
- 30
- Run by
- Targeted Therapy Technologies, LLC
See details and how to joinNCT06679634 - Phase 2Taking peopleBlinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Where
- Houston
- Age
- 14 years and over
- People
- 80
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT02877303 - No phaseTaking peopleA Registry for People With T-cell Lymphoma
- Where
- Atlanta, Aurora, Basking Ridge, Boston, Chicago, Columbus, Commack, Duarte, Harrison, Houston, Miami, Middletown, New Haven, New York, Omaha, Philadelphia, Rochester, San Diego, San Francisco, Stanford, St Louis, Tampa, Uniondale
- People
- 1,000
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT05978141 - No phaseTaking peoplePlaying Game to Learn About Children's Vaccine Project
- Where
- Chandler
- Age
- 11 years to 14 years
- People
- 180
- Run by
- Michigan State University
See details and how to joinNCT05984849 - Phase 1Taking peopleA Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
- Where
- Houston
- Age
- 1 year to 25 years
- People
- 48
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06006273 - Phase 2Taking peopleChemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
- Where
- Valhalla
- Age
- 1 year to 39 years
- People
- 20
- Run by
- New York Medical College
See details and how to joinNCT07013565 - Phase 1Taking peopleCD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
- Where
- Memphis
- Age
- Up to 21 years
- People
- 108
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT04318678 - Phase 1Taking peopleB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- Where
- Memphis
- Age
- Up to 21 years
- People
- 48
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT04897321 - Phase 1/2Taking peopleStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Where
- Atlanta, Aurora, Houston, Memphis, Minneapolis, Palo Alto, Washington D.C.
- Age
- 12 months to 30 years
- People
- 90 worldwide
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT04901702 - Phase 1/2Taking peopleSafety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- Where
- Germantown, Memphis
- Age
- Up to 30 years
- People
- 64
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT05468359 - Phase 1Taking peopleCD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
- Where
- Memphis
- Age
- Up to 21 years
- People
- 30
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT06777979 - No phaseTaking peoplexDRIVE for Florida-based Cancer Patients
- Where
- Miami
- People
- 210
- Run by
- First Ascent Biomedical Inc.
See details and how to joinNCT07167381 - No phaseTaking peopleEffects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Where
- Akron, Albuquerque, Asheville, Atlanta, Baltimore, Birmingham, Boston, Buffalo, Burlington, Charleston, Chicago, Cincinnati, Columbia, Dallas, Detroit, Duarte, Flint, Fort Myers, Fort Worth, Gainesville, Greenville, Hackensack, Hollywood, Honolulu, Houston, Jackson, Jacksonville, Las Vegas, Lebanon, Little Rock, Madera, Milwaukee, New Haven, New Hyde Park, New Orleans, Oakland, Oak Lawn, Oklahoma City, Orlando, Palo Alto, Peoria, Philadelphia, Phoenix, Portland, Providence, Richmond, Rochester, San Antonio, San Diego, Scarborough, Seattle, Spokane, St Louis, Stony Brook, St. Petersburg, Syracuse, Tampa, Tucson, West Palm Beach, Winston-Salem
- People
- 420 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT01790152 - Phase 1Taking peopleHA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Where
- Seattle
- Age
- Up to 80 years
- People
- 24
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT03326921